With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

Prescription totals for Attruby, which is locked in a closely watched commercial battle with Pfizer’s tafamidis, have more ...

Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The progress made by partner Neurocrine to advance its muscarinic agonist portfolio ... NPJ is responsible in part for provision of drug product. Strategy to expand market for daridorexant underway ...

District Judge John Bates wrote the removals harm “everyday Americans, and most acutely, underprivileged Americans, seeking ...

Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market cap of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33.

Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing ...

who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for ...

We recently compiled a list of the These 10 Firms Were Last Week's Worst Performers. In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the ...